Detection of Human CD38 Using Variable Lymphocyte Receptor (VLR) Tetramers.
evolution
flow cytometry
tetramer
variable lymphocyte receptor (VLR)
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
12 04 2020
12 04 2020
Historique:
received:
11
03
2020
revised:
03
04
2020
accepted:
10
04
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
16
3
2021
Statut:
epublish
Résumé
CD38 is a multifunctional cell surface receptor expressed on multiple cell lineages of hematopoietic origin with high levels of expression on human plasma cells. Previously, we isolated the monoclonal variable lymphocyte receptor B (VLRB) MM3 antibody from the evolutionarily distant sea lamprey, which recognized the CD38 ectoenzyme exclusively on human plasma cells in a manner that correlated with CD38 enzymatic activity. The plasma cell-specific binding of VLRB MM3 contrasts with the broad pattern of expression of CD38-determined conventional antibodies specific for this antigen. In an effort to facilitate the application of this unique reagent in combination with conventional antibody panels, we explored a strategy to generate VLRB MM3 tetramers. The resulting reagent maintained the threshold-based recognition of CD38. Increased sensitivity achieved with VLRB MM3 tetramers also showed preferential recognition of germinal center centroblasts over centrocytes. VLRB MM3 tetramers thus provided a unique and versatile single-step staining reagent for the detection of human CD38 that is readily incorporated into multi-color flow cytometry panels.
Identifiants
pubmed: 32290546
pii: cells9040950
doi: 10.3390/cells9040950
pmc: PMC7226959
pii:
doi:
Substances chimiques
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : R01 AI117818
Pays : United States
Références
Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2040-5
pubmed: 18238899
Commun Biol. 2020 Feb 28;3(1):91
pubmed: 32111965
Physiol Rev. 2008 Jul;88(3):841-86
pubmed: 18626062
Immunology. 2015 Feb;144(2):271-81
pubmed: 25155483
Front Immunol. 2018 Oct 25;9:2469
pubmed: 30410492
Structure. 2017 Nov 7;25(11):1667-1678.e4
pubmed: 28988747
FEBS Lett. 1998 Aug 21;433(3):275-8
pubmed: 9744810
Front Immunol. 2018 Nov 28;9:2722
pubmed: 30546360
Science. 1997 Oct 10;278(5336):238-9
pubmed: 9340771
Biochemistry. 2020 Feb 27;:
pubmed: 32052624
J Exp Med. 2017 Sep 4;214(9):2795-2810
pubmed: 28768709
JCI Insight. 2016;1(3):
pubmed: 27152361
Nat Immunol. 2008 Mar;9(3):319-27
pubmed: 18246071
Curr Opin Immunol. 1998 Aug;10(4):393-6
pubmed: 9722914
J Immunol. 2009 Jun 15;182(12):7595-602
pubmed: 19494283
J Immunol. 1996 Aug 15;157(4):1455-67
pubmed: 8759726
J Immunol Methods. 2012 Dec 14;386(1-2):43-9
pubmed: 22964555
Front Chem. 2019 Dec 13;7:833
pubmed: 31921763
FASEB J. 1998 May;12(7):581-92
pubmed: 9576485
Science. 1996 Oct 4;274(5284):94-6
pubmed: 8810254
J Biol Chem. 2013 Aug 9;288(32):23597-606
pubmed: 23782692
Annu Rev Immunol. 2018 Apr 26;36:19-42
pubmed: 29144837
Science. 2008 Sep 26;321(5897):1834-7
pubmed: 18818359
Structure. 2012 Sep 5;20(9):1585-95
pubmed: 22863568
J Immunol. 1993 Sep 15;151(6):3119-30
pubmed: 8397252
Nat Immunol. 2020 Mar;21(3):331-342
pubmed: 32066950
Cells. 2019 Nov 27;8(12):
pubmed: 31783629
Nature. 2009 Jun 11;459(7248):796-801
pubmed: 19474790
Nature. 2004 Jul 8;430(6996):174-80
pubmed: 15241406
Nature. 2013 Sep 19;501(7467):435-8
pubmed: 23934109
Nat Struct Mol Biol. 2009 Jul;16(7):725-30
pubmed: 19543291
Front Immunol. 2019 May 31;10:1187
pubmed: 31214171
Methods Mol Biol. 2015;1266:171-84
pubmed: 25560075
Sci Adv. 2018 Nov 07;4(11):eaar7653
pubmed: 30417091
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216